Evidence map›Paper›PMID 26056332›Full record

ArticleHypertension (Dallas, Tex. : 1979)2015

Circulating vascular cell adhesion molecule-1 is associated with cerebral blood flow dysregulation, mobility impairment, and falls in older adults.

Achille E Tchalla, Gregory A Wellenius, Thomas G Travison, Margaret Gagnon, Ikechukwu Iloputaife, Thierry Dantoine, Farzaneh A Sorond, Lewis A Lipsitz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Microvascular Health as a Key Determinant of Organismal Aging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  4. Article
  5. Article
  6. Biomarkers Involved in the Pathogenesis of Hemophilic Arthropathy.International journal of molecular sciences · 2024
    Review
  7. Article
  8. A cluster of blood-based protein biomarkers associated with decreased cerebral blood flow relates to future cardiovascular events in patients with cardiovascular disease.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Achille E TchallaFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.).
Gregory A WelleniusFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.).
Thomas G TravisonFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.).
Margaret GagnonFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.).
Ikechukwu IloputaifeFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.).
Thierry DantoineFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.).
Farzaneh A SorondFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.).
Lewis A LipsitzFrom the Institute for Aging Research, Hebrew SeniorLife, Boston, MA (A.E.T., T.G.T., M.G., L.A.L); Beth Israel Deaconess Medical Center, Boston, MA (A.E.T., T.G.T., L.A.L.); Harvard Medical School, Boston, MA (A.E.T., T.G.T., L.A.L.); Limoges University, Limoges, France (A.E.T., T.D.); IFR 145 GEIST; EA 6310 HAVAE (Disability, Activity, Aging, Autonomy and Environment), Geriatric Medicine Department, CHU Limoges, Limoges, France (A.E.T., T.D.); Brown University School of Public Health, Providence, MA (G.A.W.); and Stroke Division, Department of Neurology, Brigham and Women's Hospital, Boston, MA (F.A.S.). Lipsitz@hsl.harvard.edu.

Funding

VITAMIN D NUTRITION IN THE INSTITUTIONALIZED ELDERLYP01AG004390 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI CHENG, DEBBIE M. · 1985 to 2008
$13.2M
Translational Researchin Aging Trainnig ProgramT32AG023480 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI LIPSITZ, LEWIS · 2004 to 2024
$7.6M
Cerebral Small Vessels in Motor and Cognitive Decline: Neuroimaging Signatures of Vulnerability & ResilienceR01NS085002 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI FARZANEH A SOROND · 2014 to 2026
$3.8M
Ambient Air Pollution and Incident StrokeR01ES020871 · NIEHS · BROWN UNIVERSITY · PI WELLENIUS, GREGORY A · 2012 to 2016
$2.7M
Cerebrovascular Mechanisms of Slow Gait and FallsR01AG041785 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI LIPSITZ, LEWIS · 2013 to 2017
$2.4M
Nonlinear Dynamics of Frailty in AgingR37AG025037 · NIA · HEBREW REHABILITATION CENTER FOR AGED · PI LIPSITZ, LEWIS · 2006 to 2013
$1.6M
Cerebral Small Vessels in Motor and Cognitive Decline: Neuroimaging Signatures of Vulnerability & ResilienceRF1NS085002 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SOROND, FARZANEH A · 2022 to 2022
$1.5M
Mechanisms of Air Pollution Health Effects in Subjects with Heart FailureR00ES015774 · NIEHS · BROWN UNIVERSITY · PI WELLENIUS, GREGORY A · 2009 to 2011
$747k
NIA NIH HHS P01 AG004390NIA NIH HHS P01 AG04390NIA NIH HHS R01 AG041785NIA NIH HHS R37 AG025037NIA NIH HHS R37 AG25037NIA NIH HHS T32 AG023480NIEHS NIH HHS R00 ES015774NIEHS NIH HHS R00ES015774NIEHS NIH HHS R01 ES020871NIEHS NIH HHS R01ES020871NINDS NIH HHS NS085002NINDS NIH HHS R01 NS085002NINDS NIH HHS RF1 NS085002
6 · The paper itself

Abstract

Soluble vascular cell adhesion molecule-1 (sVCAM-1) is associated with hypertension, vascular inflammation, and systemic endothelial dysfunction. We evaluated whether elevated plasma sVCAM-1 is associated with impaired cerebrovascular function and mobility impairments in elderly people. We studied the cross-sectional relationships between plasma sVCAM-1 level, gait speed, and cerebrovascular hemodynamics, and its longitudinal relationship with falls in 680 community-dwelling participants aged ≥65 years in the Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly (MOBILIZE) Boston Study. Falls were recorded prospectively for 1 year on daily calendars. sVCAM-1 was measured by ELISA assay and beat-to-beat blood flow velocity in the middle cerebral artery during rest and in response to changes in end-tidal CO2 was measured by transcranial Doppler ultrasound. sVCAM-1 concentration was 1094±340 ng/mL in normotensives, 1195±438 ng/mL in controlled hypertensives, and 1250±445 ng/mL in uncontrolled hypertensives (P=0.008). The mean resting blood flow velocity and cerebral vasomotor range were, respectively, 41.0±10.3 cm/s and 1.3±0.4 cm/s per millimeter of mercury. Elevated sVCAM-1 levels indicative of endothelial dysfunction were associated with reduced resting blood flow velocity (P=0.017) and cerebral vasomotor range (P=0.0048). Elevated sVCAM-1 levels were associated with slower gait speed (<0.8 m/s; odds ratio, 3.01; 95% confidence interval, 1.56-5.83; P=0.0011) and an increased odds of injurious falls (odds ratio, 2.4; 95% confidence interval, 1.4-4.2; P=0.0028). An elevated sVCAM-1 level may be a marker of cerebral blood flow dysregulation because of endothelial damage from hypertension. It may also signal the presence of cerebral microvascular disease and its clinical consequences, including slow gait speed and falls.

Indexed as

Mobility LimitationAccidental FallsAgedAged, 80 and overAge FactorsBiomarkersBrainCerebrovascular CirculationCohort StudiesCross-Sectional StudiesFemaleGaitHumansHypertensionIncidenceMaleBiomarkersVascular Cell Adhesion Molecule-1brain infarctionendotheliumgaithypertension

Identifiers

PMID26056332
PMCPMC4807019

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.